243 related articles for article (PubMed ID: 10873084)
1. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
2. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
4. Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000.
Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
Clin Cancer Res; 2001 Feb; 7(2):445-7. PubMed ID: 11234903
[No Abstract] [Full Text] [Related]
5. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
[TBL] [Abstract][Full Text] [Related]
8. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
9. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Yoshida O
J Urol; 1999 Apr; 161(4):1359-63. PubMed ID: 10081908
[TBL] [Abstract][Full Text] [Related]
10. Editorial comment on: Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Babjuk M
Eur Urol; 2007 Nov; 52(5):1396-7. PubMed ID: 17466449
[No Abstract] [Full Text] [Related]
11. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.
Bianco FJ; Gervasi DC; Tiguert R; Grignon DJ; Pontes JE; Crissman JD; Fridman R; Wood DP
Clin Cancer Res; 1998 Dec; 4(12):3011-6. PubMed ID: 9865914
[TBL] [Abstract][Full Text] [Related]
12. Clinical study of urine NMP 22 (nuclear matrix protein 22) as a tumor marker in urinary epithelial cancer.
Takeuchi Y; Sawada Y; Yabuki D; Masuda E; Satou D; Kuroda K; Tajima M; Sawamura Y; Matsushima M
Aktuelle Urol; 2003 Jul; 34(4):265-6. PubMed ID: 14566681
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.
Papathoma AS; Petraki C; Grigorakis A; Papakonstantinou H; Karavana V; Stefanakis S; Sotsiou F; Pintzas A
Anticancer Res; 2000; 20(3B):2009-13. PubMed ID: 10928143
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival.
Offersen BV; Knap MM; Horsman MR; Verheijen J; Hanemaaijer R; Overgaard J
Acta Oncol; 2010 Nov; 49(8):1283-7. PubMed ID: 20843171
[TBL] [Abstract][Full Text] [Related]
15. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
Casella R; Shariat SF; Monoski MA; Lerner SP
Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
[TBL] [Abstract][Full Text] [Related]
16. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
17. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
18. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder.
Sumi T; Yoshida H; Hyun Y; Yasui T; Matsumoto Y; Hattori K; Sugimura K; Kawashima H; Nakatani T; Ishiko O
Oncol Rep; 2003; 10(2):345-9. PubMed ID: 12579270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
